Ekso Bionics (NASDAQ:EKSO) Stock Price Crosses Above Fifty Day Moving Average – Here’s Why

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)’s stock price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $6.87 and traded as high as $9.70. Ekso Bionics shares last traded at $9.52, with a volume of 310,124 shares.

Wall Street Analyst Weigh In

EKSO has been the topic of a number of recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of Ekso Bionics in a research note on Monday, December 22nd. HC Wainwright cut Ekso Bionics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 31st. Finally, Wall Street Zen raised shares of Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.50.

Ekso Bionics Trading Up 5.0%

The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.09 and a current ratio of 1.66. The company’s 50 day moving average is $6.87 and its 200 day moving average is $5.21. The stock has a market capitalization of $24.94 million, a price-to-earnings ratio of -1.68 and a beta of 0.80.

Insider Transactions at Ekso Bionics

In related news, CEO Scott G. Davis sold 23,315 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $4.80, for a total transaction of $111,912.00. Following the transaction, the chief executive officer directly owned 78,777 shares in the company, valued at $378,129.60. The trade was a 22.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Jerome Wong sold 11,288 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $4.80, for a total value of $54,182.40. Following the completion of the transaction, the chief financial officer directly owned 26,009 shares of the company’s stock, valued at approximately $124,843.20. This trade represents a 30.27% decrease in their position. The disclosure for this sale is available in the SEC filing. 6.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ekso Bionics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Consolidated Portfolio Review Corp acquired a new position in shares of Ekso Bionics in the 3rd quarter valued at $333,000. Citadel Advisors LLC acquired a new position in Ekso Bionics in the third quarter worth about $198,000. Shay Capital LLC bought a new position in Ekso Bionics during the third quarter worth about $67,000. Finally, Virtu Financial LLC acquired a new stake in Ekso Bionics during the third quarter valued at approximately $57,000. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.